Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + human chorionic gonadotropin + human menopausal gonadotropin
- Development stage
- Unknown
- Lead developer
- Jinling Hospital
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
This combination hormonal therapy regimen consists of goserelin (a GnRH agonist), human chorionic gonadotropin (hCG), and human menopausal gonadotropin (hMG). Developed and studied by Jinling Hospital in China, this specific protocol is designed for the treatment of non-obstructive azoospermia (NOA). The strategy involves an initial phase of pituitary-gonadal axis suppression using goserelin to down-regulate endogenous gonadotropin levels, which are often pathologically elevated in NOA patients. This is followed by the sequential administration of hCG and hMG to directly stimulate the Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) receptors in the testes. The goal of this 'reset and stimulate' approach is to induce spermatogenesis or improve the microenvironment for sperm production, thereby increasing the success rate of viable testicular sperm retrieval for assisted reproduction.
- Other names
- Goserelin + hCG + hMGGnRHa + hCG + hMG combination therapy
02
Targets
FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on goserelin + human chorionic gonadotropin + human menopausal gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + human chorionic gonadotropin + human menopausal gonadotropin.